YOLFTbeta
Bio-FD&C Co. Ltd.

Bio-FD&C Co. Ltd.

251120 · KQ · Healthcare / Biotechnology

7,950.00KRW-900.00 (-10.17%)

Price History

Full chart

Market Stats

Previous Close8,850.00
Open8,850.00
Day Range7,950.00 – 9,010.00
52-Week Range6,330.00 – 18,180.00
Volume81.56K
Market Cap85.12B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.38
50-Day Avg8,621.20
200-Day Avg11,996.40

About

BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, skin texture, anti-inflammation/skin soothing, and anti-oxidation. The company was founded in 2005 and is headquartered in Incheon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sang-Hyun Mo
  • Employees0
  • Headquarters509, 510, and 511, A-dong, Smartvalley, Incheon, South Korea, Korea
  • Websitehttps://www.biofdnc.com

Leadership

  • Mr. Sang-Hyun MoCo-CEO & Director · b. 1975
  • Mr. Dae-Hyeon JeongCo-CEO & Director · b. 1972
  • Mr. Changmyoung LeeHead of Management Support Division, CFO & Director · b. 1976
  • Ms. SuJeong KimMD & Executive Director · b. 1978

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.00B8.48B8.64B11.97B15.86B15.59B16.07B19.18B
Growth (%)-+41.32%+1.93%+38.57%+32.43%-1.66%+3.04%+19.37%
Cost of Revenue2.99B2.83B3.00B4.85B4.86B4.56B4.85B6.31B
Gross Profit3.00B5.65B5.64B7.13B11.00B11.03B11.21B12.87B
Gross Margin50.09%66.65%65.27%59.52%69.35%70.74%69.80%67.13%
Operating Expense2.77B2.75B2.71B3.99B6.12B6.00B6.36B6.62B
Operating Income238.49M2.90B2.92B3.14B4.88B5.03B4.85B6.25B
Operating Margin3.98%34.19%33.85%26.21%30.78%32.29%30.20%32.60%
EBITDA----6.60B8.37B6.50B9.31B
EBITDA Margin----41.63%53.66%40.48%48.54%
Net Income403.89M2.56B2.46B2.91B4.34B5.59B4.50B6.67B
Net Income Margin6.73%30.22%28.49%24.29%27.34%35.82%28.01%34.76%
R&D--738.83M815.90M1.26B1.43B1.70B1.65B
R&D as % of Total Revenue--8.55%6.82%7.92%9.16%10.57%8.61%
Interest Expense0069.67M62.29M87.88M127.82M63.47M38.94M
Interest Expense % of Total Revenue0.00%0.00%0.81%0.52%0.55%0.82%0.40%0.20%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.41B15.29B17.63B23.04B59.04B62.81B67.32B73.45B
Total Liabilities5.01B5.33B5.20B7.16B6.06B4.20B4.18B3.65B
Total Equity7.40B9.96B12.42B15.88B52.98B58.62B63.13B69.80B
Cash2.18B3.01B2.97B4.98B11.39B11.88B7.66B10.76B
Net Debt-341.83M250.91M-----

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.07B3.23B2.12B3.69B5.57B6.05B6.04B7.28B
Investing Cash Flow-202.01M-2.70B-2.44B-2.36B-30.61B-3.31B-10.31B-
Financing Cash Flow250.00M300.00M362.67M582.11M31.48B-2.23B-54.23M-
Capital Expenditure1.13B282.68M1.89B7.02B152.44M2.33B1.30B1.05B
Free Cash Flow--228.79M-3.33B5.35B3.72B4.74B6.23B
FCF to OCF--10.81%-90.33%95.96%61.48%78.52%85.59%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Feb 15, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual8.36232.0086.77174.78100.56145.80133.95275.62126.6470.39125.18205.51191.06208.05227.34156.69136.16230.96
Surprise------------------
Timing---After-hours--------------

Key Statistics & Ratios

Market Cap85.12B
Enterprise Value22.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.36
Price / Book1.07
Revenue (TTM)19.53B
Gross Profit (TTM)12.95B
EBITDA7.51B
Profit Margin32.80%
Operating Margin39.22%
Return on Equity9.19%
Return on Assets5.23%
Shares Outstanding8.53M
Shares Float5.09M
Beta0.38
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%